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2211-3355/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 26 January 2016 Severe infections caused by Haemophilus inﬂuenzae type a (Hia) have reached alarming rates in some Canadian
Aboriginal communities. We sought to estimate the frequency of exposure to this pathogen and timelines for
boosting protective antibodies.
We developed a model of secondary antigenic challenge (natural exposure), and used data for anti-Hia antibod-
ies in serum samples of healthy and immunocompromised adults in a population of Northwestern Ontario,
Canada. We parameterized the model with available estimates from previous studies for the decay rate of anti-
body and its protective levels against both Hia carriage and invasive disease. Simulations were initialized using
antibody concentrations from data.We investigated both the duration of immunity without secondary antigenic
challenge and the average time between subsequent exposures to Hia.
When there was no new natural exposure, serum antibody concentrations in healthy Aboriginal individuals
decreased below the level (1 μg/ml) assumed for protection against invasive Hia disease 3 years after primary
exposure. This period was shorter (about 2 years) for Aboriginal individuals suffering from chronic renal failure.
We estimated that a new antigenic challenge occurs once in 5 and 2 years for healthy and immunocompromised
Aboriginal individuals, respectively. More frequent natural exposure was required to maintain protective anti-
body levels for non-Aboriginal individuals compared to Aboriginal individuals.
The ﬁndings suggest that frequent boosting of natural immunity is required to maintain the anti-Hia antibody
levels protecting against invasive Hia disease, particularly in individuals with underlying medical conditions.
This information has important implications for immunization when an anti-Hia vaccine becomes available.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Haemophilus inﬂuenzae type a (Hia) is an important bacterial patho-
gen, which can cause severe invasive disease (Ulanova and Tsang,
2014). The invasive disease manifestation occurs mainly in young
children (younger than 2 years of age), the elderly, and immunocom-
promised individuals (Ulanova, 2013). Hia is one of the 6 known encap-
sulated strains of H. inﬂuenzae classiﬁed based on their distinct capsular
antigens (Ryan and Ray, 2004). H. inﬂuenzae serotype b (Hib) was the
major cause of bacterial meningitis in young childrenworldwide before
the introduction of an effective conjugate Hib vaccine in the late 1980s
(Adams et al., 1993). Routine vaccination against Hib dramatically
decreased the incidence of invasiveHib disease and carriage of the path-
ogen in the countries where vaccination programs were implemented
(Ulanova and Tsang, 2009). Since protection conferred by the Hibnosm.ca (E. Nix),
.M. Moghadas).
. This is an open access article undervaccine is speciﬁc to the type b polysaccharide capsule, widespread vac-
cination against Hib may have unmasked the disease caused by other
serotypes (Lipsitch, 1999).
The preceding decade has witnessed the emergence of Hia as the
dominant encapsulated strain of H. inﬂuenzae in several speciﬁc geo-
graphic locations and populations, including Aboriginal populations in
North America (Rotondo et al., 2013; Bruce et al., 2013). Clinical and ep-
idemiological studies of Hia indicate that Aboriginal children (younger
than 5 years of age) and adults with predisposing medical conditions
are most affected by invasive Hia disease (Ulanova, 2013). While cur-
rently there is no vaccine to prevent Hia infection, understanding of
the immunological and epidemiological characteristics of this pathogen
is imperative to develop preventive measures with long-lasting effects.
Similar to Hib, since vaccinationwith a conjugate vaccine speciﬁc to Hia
could reduce the circulation of Hia bacteria, and therefore the incidence
of Hia carriage in the population, determining timelines for boosting of
protective immunity will be essential for maintaining a high level of
herd immunity (Konini and Moghadas, 2015). In case of Hib, the fre-
quency of new exposure required to maintain protective serumthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
a)
b)
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4 years prior to the introduction of conjugated Hib vaccine (Leino et al.,
2000). Currently, there are no estimates on timelines for Hia recurrent
natural exposure and boosting of antibody concentration.
In this study, we developed amodel of secondary antigenic response
using data for anti-Hia antibody concentrations in the serum samples of
the participants in a population of Northwestern Ontario, Canada. Our
aim was to estimate the timelines for boosting antibody concentrations
following priming for different populations' characteristics. We consid-
ered the age, sex, ethnicity (Aboriginal and non-Aboriginal), and health
status (including those presenting chronic renal failure) of individuals
in stratifying collected data. Since the rates of antibody decay against
Hia are still unknown,we parameterized themodel using available esti-
mates from the published studies for Hib. We based this assumption on
the similarities between Hia and Hib capsular polysaccharide antigens
(Branefors-helander, 1977; Crisel et al., 1975).
Materials and methods
Our methodology included sample collection and laboratory assays,
data analysis, model development, simulation experiments and sensi-
tivity analysis of the model outcomes. Details of laboratory assays are
provided in the Appendix. Data collection and analysis were approved
by the Thunder Bay Regional Health Sciences and Lakehead University
research ethics boards.
Study population
This study is based on the analysis of Hia seroprevalence data in a
population of Northwestern Ontario, Canada, which is characterized
by a presence of a signiﬁcant proportion of indigenous people,
i.e., 19.6% of the total population in this area (Statistics Canada, 2006).
In comparison, according to the 2006 Canadian Census, indigenous peo-
ple comprise 3.8% of the Canadian population (Anon., 2006). Healthy
adults aged 19–80 years who self-identiﬁed as either Aboriginal or
non-Aboriginal were recruited from the Thunder Bay area. Individuals
with chronic renal failure (CRF) aged 24–91 years were recruited from
the Renal Services, Thunder Bay Regional Health Sciences Centre. The
characteristics of the study groups are presented in a recently published
study (Nix et al., 2015). Table 1 summarizes the demographic and
health status of the participating subjects.
In designing and conducting this research, we have fully adhered to
the core principles of ownership, control, access, and possession as de-
ﬁned by the National Aboriginal Health Organization and the Tri-
Council Policy Statement on Ethical Conduct for Research Involving
Humans, speciﬁcally those outlined in Chapter 9 of the ‘Research Involv-
ing the First Nations, Inuit and Métis Peoples of Canada’ (Anon., 2015;
Schnarch, 2004). In particular, prior to the beginning of the study we
engaged in an extensive consultation with a variety of stakeholders
and received letters of endorsement from several regional Aboriginal
organizations including the Nishnawbe Aski Nation (political territorial
organization representing 49 First Nation communities in Northern
Ontario), the Métis Nation of Ontario, the Red Rock Indian Band (LakeTable 1
Summary of the data collected based on the analysis of Hia seroprevalence in a population
of Northwestern Ontario, Canada.
Age/Sex Aboriginal Non-Aboriginal
Healthy CRF Healthy CRF
F M F M F M F M
19–34 29 5 2 4 10 7 2 0
35–59 23 5 14 7 13 7 4 4
≥60 3 1 8 2 5 6 6 19
All 55 11 24 13 28 20 12 23
F: female; M: male; CRF: chronic renal failure.Helen First Nation), the Bingwi Neyaashi Anishinaabek (Sand Point
First Nation), and the Fort William First Nation. During the data collec-
tion phase, we have regularly updated our Aboriginal partners through
information sessions and progress reports as results are analyzed.
Antibody concentration
On the basis of previous ﬁndings on immunological correlates of
protection against Hib disease (Leino et al., 2000; Eskola et al., 1985;
Käyhty et al., 1983), we hypothesized that anti-Hia polysaccharide anti-
body concentrations of 1 μg/ml or above provide long-term protection
against invasive Hia disease and concentrations of 5 μg/ml or above pre-
vent colonization of the upper airways. We stratiﬁed the collected data
for the level of antibody concentrations and the corresponding average
ages of individuals in Fig. 1. In all categories of healthy and CRF partici-
pants, the level of antibody concentration b1 μg/ml corresponds to the
lowest fraction of individuals, with an average age older than 50 years.
The model
We ﬁrst used logistic regression to investigate the effect of age and
sex on the concentration of anti-Hia capsular polysaccharide antibody
in the serum samples of the study participants. The statistical signiﬁ-
cance of adding the interaction term for age and sex was assessed by
using a likelihood ratio test.We performed this analysis for bothAborig-
inal and non-Aboriginal participants. All tests were at two-sided signif-
icance level of 0.05. The results of this analysis indicated that variables of
sex and age were not signiﬁcant on the level of antibody concentration,Fig. 1. (a) The fraction of individuals at low risk of infection (AC ≥ 5 μg/ml; light grey), low
risk of invasive disease (1 μg/ml ≤ AC b 5 μg/ml; dark grey); and high risk of invasive
disease (AC b 1 μg/ml; black). (b) The corresponding average ages of individuals
identiﬁed as healthy Non-Aboriginal (NAb-H); Non-Aboriginal with chronic renal failure
(NAb-CRF); healthy Aboriginals (Ab-H); and Aboriginals with chronic renal failure
(Ab-CRF). (AC: total IgG and IgM antibody concentration).
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pendent of these variables.
Antibody boosting
We assumed that in the absence of any boosting, the initial antibody
level decays in the exponential form c(t)=c0e−k(t−t0)a, where c(t) is the
antibody concentration at time t; c0is the initial concentration, k is the
decay rate (per time); and a is the parameter regulating the antibody
decline in the range 0–1 (Auranen et al., 1999).
When stimulating challenge occurs after time t0, the antibody con-
centration is increased in the process of boosting immune responses.
The level of boosting, however, depends on c(t) at the time of natural
exposure. Consistent with previous work (Ulanova and Tsang,
2014; Chokephaibulkit et al., 2004; Concepcion and Frasch, 1998;
Hawdon et al., 2012), we considered two threshold levels of antibody
concentrations:
i) Subclinical threshold (L1): concentration above this level prevents
the development of subclinical disease (carriage) following expo-
sure, and a minimal stimulation of the immune system may occur.
ii) Invasive threshold (L2): concentration above this level, but below L1
is not adequate for infection protection. However, this level of anti-
body concentration will mitigate infection if occurs, and prevent
invasive form of disease. Exposure to infection during the period in
which L2bc(t)bL1 leads to a moderate boosting of the immune
response and a measurable increase in the level of antibody
concentration.
The maximum level of boosting occurs when c(t)bL2, especially
when the individual is naïve. Due to the possibility of boosting immuni-
ty following priming, we enhanced the exponential decay model to
include the increase in the level of antibody concentration. We consid-
ered c′(t)=−kc(t)+b(t), where b(t) is the boosting rate at the time
of natural exposure. This rate depends on several key parameters, and
we used the Heaviside step function to describe the increase in c(t)
(Fowler, 1981). We deﬁned
θ tð Þ ¼ β H L1−c tð Þð Þ þ H L2−c tð Þð Þ½ 
1þ H L1−c tð Þð Þ ;
where β is the maximum boosting rate in the absence of pre-existing
immunity. Denoting the average time for a secondary natural exposure
following priming by τ, we deﬁned b(t)=θ(t)δ(t−nτ), for n=1,2,⋯,
where Kronecker δ is deﬁned by:
δ t−nτð Þ ¼ 1 if t ¼ nτ0 if t ≠ nτ

This functional form of boosting allows for the increase in the anti-
body concentration based on the amount of c(t) at the time of natural
exposure. We estimated the rate of boosting β=cm as a result of new
natural exposure following priming, where cm is the geometric mean
concentration (GMC) of the measurements for antibody concentration.
For antibody concentrations below L2, the magnitude of simulated
boosting response was full at the time of exposure (that is similar to
the case where there is no preexisting immunity). This magnitude re-
duced by 50% (as deﬁned in θ(t)) for antibody concentrations between
L2 and L1 at the time of exposure.
Parameterization and simulations
We parameterized the model using available estimates from the
published studies for Hib. In the absence of vaccination, the duration
and the decline rate of antibody concentration depend on the incidence
of infection in the population (Leino et al., 2000). We assumed a decay
rate in the range of 0.08–0.16 per year (converted to a rate permonth) (Leino et al., 2000), and used antibody concentration levels of
L1=5 and L2=1 (μg/ml) for preventing subclinical infection and inva-
sive disease, respectively. Previous work pertinent to Hib indicates
that individuals with antibody concentrations above 1 μg/ml were
protected against invasive disease despite the occurrence of infection
(Leino et al., 2000; Eskola et al., 1985). The Latin Hypercube Sampling
(LHS) technique was used to evaluate the effect of simultaneous varia-
tion of model parameters on the outcomes.
Parameter variation and sampling
To determine the timelines for decline of antibody concentration,we
used the Latin Hypercube Sampling (LHS) technique (McKay et al.,
1979) and ran simulations for a 10-year period following priming,
when k and a are given by LHS. To allow for the simultaneous variations
of these parameters, samples of size n= 100 were generated in which
each parameter was treated as a random variable and assigned a prob-
ability function. These parameters were uniformly distributed and sam-
pled within their respective ranges. Each parameter set was simulated
using the total IgG and IgM antibody concentrations measured for
each individual in the collected samples as the initial condition at time
t0. For each scenario, corresponding to the average number of years
for a new natural exposure, we ran 1000 independent simulations,
and determined the geometric mean concentration (GMC) and 95%
conﬁdence intervals of the antibody concentration within 10 years.
Results
Duration of immunity without secondary antigenic response
For scenarios in which there is no new natural exposure, we ob-
served that the level of antibody concentration in healthy Aboriginal in-
dividuals would be expected to fall below the level (1 μg/ml) assumed
for protection against invasive disease 3 years after priming (Fig. 2a,
black curve). The period of protection against invasive disease is shorter
(2 years) for immunocompromised Aboriginal individuals suffering
from CRF (Fig. 2a, red curve). The corresponding protection periods
against invasive disease for non-Aboriginals are 2 years (for healthy
individuals) and 1 year (for individuals with CRF condition), as shown
in Fig. 2b.
Average time between exposures
We simulated the model to estimate the average time within which
a new natural exposure will need to occur in order to maintain the
population level of antibody concentration above 1 μg/ml. For Aborigi-
nal individuals, we estimated this average time to be 5 and 2 years for
healthy and CRF subjects, respectively (Fig. 2c and d). For healthy
non-Aboriginals, a new natural exposure was estimated to occur once
in 2 years. We estimated a higher frequency (once every year) of new
natural exposure to prevent the risk of invasive disease in non-
Aboriginals with CRF condition.
Discussion
In this study, wemade a systematic attempt to develop amodel that
can be used to estimate timelines for boosting protective antibody con-
centrations following priming. Our results, based on parameter esti-
mates for Hib, indicate that Hia colonization may be occurring more
frequently in some populations, such as North American indigenous
people, compared to previous estimates for Hib (Leino et al., 2000). In-
deed, recent studies indicate that Aboriginal adults have signiﬁcantly
higher serum bactericidal activity against Hia compared to non-
Aboriginal individuals living in the same geographic area suggesting
an increased exposure to the pathogen in the former population (Nix
et al., 2015). Although current rates of Hia colonization in the North
a) b)
d)c)
Fig. 2. Themedian GMC antibody levels with their predictive 95% conﬁdence intervals over a 10-year time period following priming, without (a and b) and with a new natural exposure
(c and d). The risk of carriage is shown in grey area. Black and red curves correspond to healthy and CRF subjects, respectively. For Aboriginals (panel c), new natural exposure occurred
once in 5 years for healthy individuals (black curve) and once in 2 years for individuals with CRF condition (red curve). For non-Aboriginals (panel d), new exposure occurred once in
2 years for healthy individuals (black curve) and once every year for individuals with CRF condition (red curve).
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against this pathogen are unknown, our data suggest that adult serum
antibody concentrations are above the threshold required for the pre-
vention of Hia invasive disease in the Aboriginal populations of North-
western Ontario (Canada). Our model indicates that frequent natural
exposure is required to maintain the anti-Hia capsular polysaccharide
antibody levels against invasive Hia disease, particularly in individuals
with chronic renal failure who are immunocompromised as a result of
profoundmetabolic consequences of uremia, underlyingmedical condi-
tions (e.g., type 2 diabetes mellitus), and hemodialysis procedure
(Betjes, 2013).
Severe infections caused by Hia have reached alarming rates in
terms of morbidity in Canadian Aboriginal communities (Ulanova and
Tsang, 2014). The case-fatality rate of invasive Hia disease among pedi-
atric cases reported by Canadian IMPACT centers in 1996–2001 reached
16% (McConnell et al., 2007). From 2000 to 2010, 56% of identiﬁed cases
of invasive H. inﬂuenzae disease with serotype information were caused
byHia in Canadian northern populations, with average invasive Hia dis-
ease of 4.6 cases per 100,000 population per year over these 11 years
(Rotondo et al., 2013). The reasons behind the vulnerability of Aborigi-
nal people to invasive Hia disease are unknown, but could be related to
biological and environmental factors, both requiring a systematic study.
In the pre-Hib vaccine era, the indigenous populations of North America
and Australia experienced the highest incidence rates of invasive Hib
disease worldwide (Ward et al., 1981; Losonsky et al., 1984; Hansmanet al., 1986; Hanna, 1990). However, the experience with Hib vaccines
over the past 20 years has demonstrated that even highly vulnerable
populations can be successfully protected using immunization with
protein–polysaccharide conjugated vaccine (Santosham et al., 1992;
Singleton et al., 2006). Therefore, the immunization of vulnerable pop-
ulations against Hia may be a solution to reduce incidence, and possibly
control Hia disease in affected communities.
Immunization can induce indirect protection through herd immuni-
ty, which reduces pathogen transmission in the population. This can
have a profound impact on immunity at the individual level, as protec-
tive antibody titers decline over time without boosting, which will in
turn affect the levels of herd immunity. Our ﬁndings in this study
highlight the importance of vaccination and timely boosting of the
individual's immunity within the expected duration of vaccine-
induced protection against Hia. Such information on the required fre-
quency of boosting immunity is essential for the development of vacci-
nation policies that have long-lasting effects on curtailing Hia incidence
(Konini and Moghadas, 2015).
Our study has several limitations that highlight the need for further
investigations and data collection in speciﬁc population settings. First
and foremost is the fact that we parameterized our model with the
range of antibody decay previously estimated for Hib prior to vaccina-
tion. However, to estimate the Hia-speciﬁc decay rates of antibody con-
centrations in the absence of vaccination, subsequent measurements of
serum samples should be collected for several years. While such data
149A. Konini et al. / Preventive Medicine Reports 3 (2016) 145–150can provide better estimates of timelines for boosting concentrations,
we note that antigens from several organisms other than Hia can
also induce cross-reactive antibodies to Hia capsular polysaccharide
(Lagergard and Branefors, 1983; Fekete et al., 2006), and may therefore
increase the antibody concentration. Since the relative importance of
antibodies arising in response to encounters with cross-reactive bacte-
ria is unknown, the measurements of the serum Hia antibody concen-
tration may not be reliable in detecting carriage. We assumed the
same subclinical infection and invasive disease thresholds for both Ab-
original and non-Aboriginal populations. However, given the reported
incidence of Hia in the northern communities of Canada (Ulanova and
Tsang, 2014; Rotondo et al., 2013; McConnell et al., 2007), it may be
the case that these thresholds are higher for Aboriginal populations
compared to non-Aboriginal populations. These considerations merit
further investigation.
Nevertheless, it is important to recognize that self-identiﬁcation as
Aboriginal comes with signiﬁcant admixture and that biological or
genetic differences are unlikely to play a signiﬁcant role in accounting
for the current epidemiology of invasive Hia disease. The social determi-
nants of health, which Aboriginal people have had to endure, are very
likely to be a major factor combined with the geographical characteris-
tics of the population. The city where the data have been collected
(Thunder Bay, Ontario) is a hub for the region and many Aboriginal
people living/working in the city regularly visit their home communi-
ties, whichmay lead to increased exposure. These factorsmay potential-
ly explain the differences in antibody concentrations between the
groups.Conclusions
The measurements of antibody concentration in the data used for
this study show that a signiﬁcant fraction of participants have anti-Hia
antibody levels above 1 μg/ml. Our model suggests that frequent
boosting of immunity through natural infection is required to maintain
protective antibody levels above 1 μg/ml observed in the data. Among
factors that could affect the incidence rate of Hia carriage and disease,
and therefore herd immunity in the population, are socio-economic
and environmental conditions, particularly in Canadian northern com-
munities with predominantly Aboriginal populations (Tsang et al.,
2014). These factors warrant further investigation for understanding
the biological and epidemiological mechanisms responsible for high
prevalence of Hia circulation in these population settings. Although ge-
netic differences between Aboriginal and non-Aboriginal populations
may be obscured by admixture, the role of epigenetic factors associated
with social determinants of health may be more important. Under-
standing of these complex factors will be essential for implementing
immunization and booster strategies (Konini and Moghadas, 2015)
with long-lasting effects when an anti-Hia vaccine candidate becomes
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